NewsDialy

Sanofi Pompe disease drug shortage hits Myozyme and Nexviazyme as FDA flags Waterford plant

8/10/2026

Two medicines used to treat Pompe disease, a rare inherited muscle disorder caused by the abnormal buildup of glycogen in the body's cells, are running short across the United States and Europe.

Sanofi, which manufactures both drugs, has alerted patient groups and physicians that supplies of Myozyme and Nexviazyme are dwindling.

The disruption emerged shortly after the Food and Drug Administration warned the company about manufacturing problems at its facility in Waterford, Ireland, where both medicines are produced.

The FDA warning and what followed The FDA flagged manufacturing issues at the Waterford plant, and the supply shortfall followed.